68Ga-FAPI PET/CT用于转移性多形性小叶乳腺癌分期与疗效评估
本文报道一例复发性转移性多形性小叶乳腺癌,基线68Ga-FAPI PET/CT显示的广泛区域及远处病变程度超过18F-FDG PET/CT。启动奥拉帕利治疗后系列随访FAPI PET/CT显示显著应答、病变接近完全消退,提示FAPI PET/CT在小叶乳腺癌疗效评估中的潜在价值。
要点
- 68Ga-FAPI PET/CT在乳腺癌尤其是浸润性小叶癌中敏感性高于18F-FDG PET/CT。
- 本例基线FAPI PET/CT显示的病变范围被18F-FDG PET/CT低估。
- 奥拉帕利治疗后系列FAPI PET/CT示显著应答、病变接近完全消退。
核心结论
- FAPI PET/CT在小叶乳腺癌疗效评估中可能具有应用价值。
研究设计与样本
- 本文为单例病例报告,报道一例复发性转移性多形性小叶乳腺癌患者。
主要发现
- 基线68Ga-FAPI PET/CT显示广泛区域及远处病变,其范围被18F-FDG PET/CT低估。
- 启动奥拉帕利后系列随访FAPI PET/CT显示显著应答,病变接近完全消退。
临床怎么用
- 对浸润性小叶乳腺癌可考虑FAPI PET/CT以更全面评估病变范围。
- FAPI PET/CT可用于奥拉帕利治疗后的系列疗效随访评估。
局限性
- 仅为单例病例报告,FAPI PET/CT用于疗效评估的作用仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68 Ga-FAPI PET/CT has demonstrated higher sensitivity than 18 F-FDG PET/CT in breast cancer, particularly in invasive lobular carcinoma. However, its role in treatment response assessment remains limited. We report a case of recurrent metastatic pleomorphic lobular breast cancer in which baseline 68 Ga-FAPI PET/CT revealed extensive regional and distant disease underestimated by 18 F-FDG PET/CT. Serial follow-up FAPI PET/CT after initiation of olaparib demonstrated marked response with near complete resolution of disease, highlighting the potential utility of FAPI PET/CT for response assessment in lobular breast cancer.
引用
- Al Riyami K, Jain A, Al Busaidi A, et al. Beyond FDG: Serial 68 Ga-FAPI PET/CT for Staging and Treatment Response Assessment in Metastatic Pleomorphic Lobular Breast Cancer. Clin Nucl Med. 2026. PMID: 42149908. doi:10.1097/RLU.0000000000006540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。